Blockchain Registration Transaction Record
Silo Pharma Secures Key Patent for PTSD Treatment, Advances Clinical Trials
Silo Pharma (NASDAQ: SILO) gains U.S. patent for PTSD treatment biomarkers, advancing Phase 1 trials for SPC-15. A breakthrough in mental health therapeutics.

This development is crucial as it represents a significant advancement in the treatment of stress-induced affective disorders, including PTSD, a condition affecting millions worldwide. Silo Pharma's innovative approach, particularly with SPC-15, could offer a new, effective treatment option, addressing a critical unmet need in mental health care. The company's progress underscores the potential of psychedelic and novel therapeutics in transforming psychiatric treatment paradigms.
Blockchain | Details |
---|---|
Contract Address | 0xeA2912a8DA1CD48401b10cB283585874d98098F4 |
Transaction ID | 0x5ff413d83d6b83fc0298cd30ee0c1ab8bd2cc94da2abb908cd722bc3cc5a080f |
Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
Chain | polygon-main |
NewsRamp Digital Fingerprint | coolCyDw-45651e6961f6d5c8a4dfcfec702c620f |